|
Project ACHIEVE (AIDS Community Health Initiative Enroute to a Vaccine Effort) is committed to conducting HIV prevention research and education.
Our research studies are devoted to evaluating the safety and efficacy of strategies to prevent HIV infection, especially HIV preventive vaccines. We rely on community participation and direction to ensure that our research is appropriate, meaningful and beneficial.
Project ACHIEVE is a part of the Laboratory of Infectious Disease Prevention of the New York Blood Center. Project ACHIEVE is funded by the National Institutes of Health (NIH) HIV Vaccine Trials Network (HVTN), an international, government-funded trials network created to speed the development of an HIV/AIDS vaccine. Project ACHIEVE and its partner, Columbia University, make up the HIV Vaccine Trials Unit (HVTU) of New York City.
|
 |
RESEARCH
Our trials involve HIV uninfected men and women and seek to find out if a vaccine can prevent infection or diminish disease progression after infection with the HIV virus. We recently participated in the first-ever phase III HIV preventive vaccine trial. While our past research has primarily focused on men who have sex with men (MSM) and women at risk of HIV infection through heterosexual exposure, we have now expanded our research to include both high- and low-risk men and women of all sexual orientations.
Project ACHIEVE's principal investigator is Beryl Koblin, PhD, an epidemiologist. She is Head of the Laboratory of Infectious Disease Prevention at the New York Blood Center. Beryl is also an adjunct faculty member at the Mailman School of Public Health, Columbia University.
EDUCATION
In addition to our research, we continue to educate the community to build awareness for the need for a vaccine, to build acceptance and support for vaccine research, and to encourage advocacy for new trials. We achieve this through a variety of ways, including group presentations and workshops, conferences, and newsletters.
PARTNERS
Project ACHIEVE and Columbia University Medical Center work together to conduct phase I, II, and III trials of candidate preventive HIV vaccines. We also partner with Bronx-Lebanon Medical Center, which investigates microbicides to prevent HIV infection. |
ONGOING
STUDIES 
